Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4022/jafib.1250 http://scihub22266oqcxt.onion/10.4022/jafib.1250 C4682916!4682916!27957180     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27957180&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Atr+Fibrillation 2015 ; 8 (1): ä Nephropedia Template TP {{tp|p=27957180|t=2015. Anticoagulation in Heart Failure: a Review |pdf=|usr=}}{{27957180}} gab.com Text Anticoagulation in Heart Failure: a Review JO: J Atr Fibrillation http://www.kidney.de/pget.php?&tw=1&pmid=27957180 #FOAvip Heart failure (HF) with reduced left ventricular function inflicts a large and growing burden of morbidity and mortality in the US and across the globe. One source of this burden is stroke. While it appears that HF itself may impose some risk of stroke, it is in the presence of other risk factors, like atrial fibrillation, that the greatest risks are observed. Therapeutic anticoagulation is the mainstay of risk reduction strategies in this population. While warfarin was the only available therapy for anticoagulation for many decades, there are now four direct oral anticoagulants available. In three of these four, outcomes in the specific subgroup of patients with heart failure have been examined. In this review, we provide some pathophysiologic basis for the risk of stroke in heart failure. In addition, the available therapeutic options for stroke risk prevention in heart failure are described in detail including how these options are incorporated into relevant professional society guidelines. Twit Text FOAVip Anticoagulation in Heart Failure: a Review ????J Atr Fibrillation http://www.kidney.de/pget.php?&tw=1&pmid=27957180 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27957180 #FOAvip English Wikipedia <ref>{{Cite pmid|27957180}}</ref> Anticoagulation in Heart Failure: a Review #MMPMID27957180 Zeitler EP; Eapen ZJ J Atr Fibrillation 2015[Jun]; 8 (1): ä PMID27957180show ga Heart failure (HF) with reduced left ventricular function inflicts a large and growing burden of morbidity and mortality in the US and across the globe. One source of this burden is stroke. While it appears that HF itself may impose some risk of stroke, it is in the presence of other risk factors, like atrial fibrillation, that the greatest risks are observed. Therapeutic anticoagulation is the mainstay of risk reduction strategies in this population. While warfarin was the only available therapy for anticoagulation for many decades, there are now four direct oral anticoagulants available. In three of these four, outcomes in the specific subgroup of patients with heart failure have been examined. In this review, we provide some pathophysiologic basis for the risk of stroke in heart failure. In addition, the available therapeutic options for stroke risk prevention in heart failure are described in detail including how these options are incorporated into relevant professional society guidelines. äAnticoagulation in Heart Failure: a Review (epmc).pdf DeepDyve Pubget Overpricing